|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Amylin Pharmaceuticals Inc., of San Diego, reported positive Phase I results for AC3056, a compound being evaluated for the treatment of atherosclerosis and other conditions related to blood vessel obstruction. In the double-blind, placebo-controlled crossover study, 14 healthy subjects received an oral formulation of AC3056 administered in a dose-rising manner. Dose-dependent increases in blood levels of AC3056 were observed, showing absorption following oral administration. Dose-dependent increases in serum antioxidant activity were also observed. No safety concerns were noted.
Atlantic Technology Ventures Inc., of New York, reported at last week's U.S. Army ...